Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Zelira Therapeutics ( (AU:ZLD) ).
Zelira Therapeutics has advanced its HOPE® Autism Spectrum Disorder program by securing a fourth funding tranche of US$681,000 to progress its FDA trial process. This funding marks a significant step towards conducting FDA Phase 1 clinical trials, focusing on treating irritability in patients with Phelan McDermid Syndrome comorbid with ASD, highlighting the potential of the HOPE® program to meet significant unmet medical needs.
More about Zelira Therapeutics
Zelira Therapeutics Ltd, listed on ASX and OTCQB, is a global leader in developing and commercializing clinically validated cannabinoid-based medicines.
YTD Price Performance: -1.32%
Average Trading Volume: 421
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $4.24M
For a thorough assessment of ZLD stock, go to TipRanks’ Stock Analysis page.
